GREY:ATBPF - Post by User
Comment by
CalgaryATEon Jun 24, 2021 2:25am
201 Views
Post# 33439977
RE:RE:RE:RE:Conference Call Tomorrow ...
RE:RE:RE:RE:Conference Call Tomorrow ...MrMugsy wrote: GameChangerBet wrote: No new material from what I heard.
Although reassuring of all the material positives in the near-intermmediate term.
themagicbox wrote: were you able to catch it any details? It just ended.
MrMugsy wrote: Raymond James tomorrow at 8:40 AM.
Based on the Bear Creek call today - sounds like a few things might be made a little clearer tomorrow (from what others are saying).
Someone remind Yukon not to take my advice ... he's too good to take that call anyway.
: )
Finished off the discussion with a reminder that OTENA peak sales of $4B is in reference to OA in 4 markets. Looking at all indications ... OTENA is probably looking at $10B for peak. If I understood that final comment.
Only had time for two questions
After listening to it at my leisure tonight, the first question & answer was in regards to how were they planning on handling the placebo effect. A little bit more detail on the 2nd question was:
Q (29:00): Total addressable market is far more significant beyond OA, plans for label expansion beyond OA?
A: (29:30): graph on investor deck ($4 billion US sales at peak), only for 7 markets (5 in Europe, US & Japan, representing 65% of the world) and only for OA (about 50% of the overall chronic pain indication). Going to go after all of it. OA is solid and robust, great way to go after initial marketing approval with FDA and other agencies. As they're reviewing the file, we will rapidly do the other studies (they're smaller), go after rheumatoid arthritis and ankylosing spondylitis and other chronic pain indications (same size as the OA market), will constantly be doing that. At 21% adoption could be seeing peak sales of close to 10 billion dollars per year.
https://kvgo.com/rj-health/antibe-therapeutics-inc-june-2021